These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7871089)

  • 1. Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole.
    Willner P; Lappas S; Cheeta S; Muscat R
    Psychopharmacology (Berl); 1994 Aug; 115(4):454-62. PubMed ID: 7871089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia.
    Papp M; Willner P; Muscat R
    Psychopharmacology (Berl); 1993; 110(1-2):159-64. PubMed ID: 7870877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline.
    Muscat R; Papp M; Willner P
    Psychopharmacology (Berl); 1992; 109(4):433-8. PubMed ID: 1365858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant.
    D'Aquila P; Monleon S; Borsini F; Brain P; Willner P
    Eur J Pharmacol; 1997 Dec; 340(2-3):121-32. PubMed ID: 9537806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer.
    Cheeta S; Broekkamp C; Willner P
    Psychopharmacology (Berl); 1994 Dec; 116(4):523-8. PubMed ID: 7701058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress.
    Papp M; Muscat R; Willner P
    Psychopharmacology (Berl); 1993; 110(1-2):152-8. PubMed ID: 7870876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress.
    Papp M; Willner P; Muscat R
    Psychopharmacology (Berl); 1991; 104(2):255-9. PubMed ID: 1876670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioural evidence that different neurochemical mechanisms underly stretching-yawning and penile erection induced in male rats by SND 919, a new selective D2 dopamine receptor agonist.
    Ferrari F; Pelloni F; Giuliani D
    Psychopharmacology (Berl); 1993; 113(2):172-6. PubMed ID: 7855178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential antidepressant properties of pramipexole detected in locomotor and operant behavioral investigations in mice.
    Lehr E
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):495-500. PubMed ID: 12373450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.
    Siuciak JA; Fujiwara RA
    Psychopharmacology (Berl); 2004 Sep; 175(2):163-9. PubMed ID: 14985923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antidepressant effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    J Neural Transm (Vienna); 1997; 104(4-5):525-33. PubMed ID: 9295183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sucrose intake: increase in non-stressed rats and reduction in chronically stressed rats are both prevented by the gamma-hydroxybutyrate (GHB) analogue, GET73.
    Tacchi R; Ferrari A; Loche A; Bertolini A
    Pharmacol Res; 2008 Jun; 57(6):464-8. PubMed ID: 18573666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.
    Hall ED; Andrus PK; Oostveen JA; Althaus JS; VonVoigtlander PF
    Brain Res; 1996 Dec; 742(1-2):80-8. PubMed ID: 9117424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors.
    Mierau J; Schneider FJ; Ensinger HA; Chio CL; Lajiness ME; Huff RM
    Eur J Pharmacol; 1995 Jun; 290(1):29-36. PubMed ID: 7664822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress.
    Pothion S; Bizot JC; Trovero F; Belzung C
    Behav Brain Res; 2004 Nov; 155(1):135-46. PubMed ID: 15325787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The adrenergic α2 antagonist atipamezole alters the behavioural effects of pramipexole and increases pramipexole concentration in blood plasma.
    McCormick PN; Fletcher PJ; Wilson VS; Remington GJ
    Life Sci; 2016 Apr; 151():300-304. PubMed ID: 26976325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sexual attraction and copulation in male rats: effects of the dopamine agonist SND 919.
    Ferrari F; Giuliani D
    Pharmacol Biochem Behav; 1995 Jan; 50(1):29-34. PubMed ID: 7700951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine.
    Papp M; Klimek V; Willner P
    Psychopharmacology (Berl); 1994 Aug; 115(4):441-6. PubMed ID: 7871087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats.
    Dardou D; Chassain C; Durif F
    Front Neurosci; 2014; 8():437. PubMed ID: 25610366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.